Trial Profile
A retrospective,single,center study to compare the rate of cytomegalovirus infection in kidney transplant recipients who recieved subtherapeutic versus therapeutic Valganciclovir prophylaxis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 May 2017
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 07 May 2017 New trial record
- 03 May 2017 Results presented at the 2017 American Transplant Congress